Oncosec Medical (ONCS) Tops Q3 EPS by 6c

Oncosec Medical (NASDAQ: ONCS) reported Q3 EPS of ($0.22), $0.06 better than the analyst estimate of ($0.28).

At April 30, 2017, OncoSec had $16.1 million in cash and cash equivalents, as compared to $28.7 million of cash and cash equivalents at July 31, 2016. OncoSec, based on its current rate of cash consumption, estimates it will need additional capital in the first calendar quarter of 2018 to continue to operate its business.

For earnings history and earnings-related data on Oncosec Medical (ONCS) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Outlook Therapeutics (OTLK) Misses Q3 EPS by 9c
• HeartCore Enterprises, Inc. (HTCR) Misses Q2 EPS by 185c